Incept, LLC

Ocular Therapeutix, Inc.

Other

Rami El-Hayek

Peter K Jarrett

Charles D Blizzard

Amarpreet S Sawhney

Michael Goldstein

Timothy S Jarrett

Andrew Vanslette

Michael J McGrath

Andrew C Vanslette

Courtney A Rosales

Arthur Driscoll

Joseph Iacona

Erica Kahn

Zachary Lattrell

Sarah Guedez

Michael J Mcgrath

The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Ocular implant containing a tyrosine kinase inhibitor

Provided herein are sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent

Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine

Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.

Shape changing drug delivery devices and methods

Serial-solvent biomaterials are described. Embodiments include materials made in an organic solvent that are stripped of the solvent and used in a patient, where they imbibe water and form a hydrogel. These materials are useful for, among other things, delivering therapeutic agents, tissue augmentation, and radiological marking.

Medical organogel processes and compositions

This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.

Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor

Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. The agent may be essentially insoluble in water. The hydrogel may be made so that 50% to 100% w/w of the agent is released when the hydrogel is from 100% to 50% persistent, with the persistence being a measure of the dry weight of the hydrogel relative to an initial dry weight of the hydrogel.

Growing community of inventors

Norwood, MA, United States of America

Rami El-Hayek